You are here: Industry Insights > Regulus Therapeutics

News List

First Patient Dosed in RGLS4326 Trial for Autosomal Dominant Polycystic Kidney Disease americanpharmaceuticalreview
October 22, 2020
Regulus Therapeutics announced initiation of dosing in its Phase 1b clinical study of RGLS4326 in patients with ADPKD.
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) prnewswire
October 16, 2020
Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced initiation of dosing in its Phase 1b clinical study of RGLS4326 in patients with ADPKD.
Regulus Therapeutics Reinitiates RGLS4326 Study for ADPKD Treatment americanpharmaceuticalreview
March 10, 2020
Regulus Therapeutics has initiated dosing of the second cohort of its Phase 1 multiple ascending dose clinical trial (the "MAD study") of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Regulus Therapeutics Announces RGLS4326 Program Hold americanpharmaceuticalreview
July 25, 2019
Regulus Therapeutics announced a program update for RGLS4326 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Company has been working with the United States Food and Drug Administration (FDA) since July 2018 ...
WuXi STA and Regulus announce microRNA development and manufacturing collaboration cphi-online
February 26, 2018
Agreement follows the recent opening of WuXi STA's oligonucleotide R&D labs in China and the US.
Aptuit announces agreement with Regulus Therapeutics June 15, 2017
Aptuit's strategic provider agreement with Regulus Therapeutics provides range of discovery, CMC and non-clinical services.